The NbN was developed because it has become clear that the current pharmacological nomenclature of psychotropic medications does not reflect our contemporary knowledge, nor does it appropriately inform the clinician about neuroscience-based prescribing. Very often we prescribe “antidepressants” for “anxiety” disorders or “second generation antipsychotics” to depressed patients.
This practice is confusing.
• The mission of NbN is to embed our current neuroscience advances in the nomenclature.
• The scope is to include all medications with CNS indications and to harness this new nomenclature to help clinicians when they are trying to figure out what would be the next rational “neuropsychopharmacological step”.
This proposed nomenclature aims to reflect the current pharmacology knowledge base and cannot necessarily represent the ultimate scientific truth.
The taskforce that assembled this app could have taken the stand that our current knowledge base is not enough to define the exact pharmacological domain or the correct mechanisms of action. However, as a taskforce, we feel that it’s better to present a cutting-edge scientific interpretation than to wait for the definitive conclusion. After all, we need to treat our patients now, and we cannot postpone treatment until all the facts are known.
Therefore this nomenclature is based on:-
1. The need to treat now
2. Updated neuroscience insights
3. The judgment of the members of the taskforce
4. The assumption that children are developing and therefore developmental aspects (e.g. liver and kidney function, brain developmental stage) must be considered in use and dosage.
Along these lines, we have come up with a nomenclature that is driven by: pharmacology and mode of action. The NbN reflects current knowledge and understanding regarding neurotransmitters / molecules / systems being modified + mode / mechanism of action

4 clinically relevant dimensions are also included:
1.Approved indications – Based on the recommendations of major regulatory bodies (e.g. FDA, EMA, etc.) for this age group.
2. Efficacy and side effects – Aimed to highlight situations in which a compound has no formal approval for an indication, yet there is evidence to support its use in additional indication(s), for example well supported expert guidelines.
In the side effects section, only serious, life-changing or prevalent side-effects are listed.
3. “Practical notes” – Summarizes the clinical knowledge that has been "filtered" though the taskforce "sieve".
4. Neurobiology – Derived from empirical data.
For those who would like to know more about the pharmacology there is a direct link to the relevant site of IUPHAR – our collaborator in this endeavor.

As this is an on-going process, we recognize that there are going to be omissions. Based on your feedback, other colleagues’ responses (the “wisdom of clinicians”), new reports and new findings, appropriate updates will be undertaken.

NbN C&A embeds current neuroscience advances in order to provide a comprehensive and coherent naming system for children and adolescence. The taskforce hopes that it will help clinicians to make informed decisions in their "psychopharmacological steps" and that it clarifies the rationale for prescribing.

NBN ilitengenezwa kwa sababu imekuwa wazi kuwa sasa za dawa utaratibu wa majina wa dawa za akili haionyeshi elimu yetu ya kisasa, wala gani ipasavyo taarifa Daktari kuhusu maagizo sayansi ya ubongo-msingi. Mara nyingi sana sisi kuagiza "dawamfadhaiko" kwa "wasiwasi" matatizo au "vizuia magonjwa ya akili pili kizazi" kwa wagonjwa huzuni.
Zoezi hili ni utata.
• Ujumbe wa NBN ni kupachika sayansi ya ubongo wetu wa sasa maendeleo katika utaratibu wa majina.
• wigo ni pamoja dawa zote na mifumo mingi dalili na kuunganisha utaratibu wa majina haya mapya ya kusaidia madaktari wakati wao ni kujaribu kufikiri nini itakuwa ya mantiki "hatua neuropsychopharmacological".
Hii utaratibu wa majina ya mapendekezo inalenga kutafakari sasa taaluma ya dawa msingi wa elimu na wanaweza si lazima kuwakilisha mwisho kisayansi ukweli.
Jopokazi kwamba wamekusanyika programu hii inaweza wamechukua msimamo kwamba ujuzi wetu wa sasa msingi haitoshi kuelezea halisi za dawa uwanja au taratibu sahihi wa utekelezaji. Hata hivyo, kama kikosi kazi, tunafikiri kwamba ni bora sasa avancerad kisayansi tafsiri ya kusubiri kwa hitimisho bainifu. Baada ya yote, tunahitaji kutibu wagonjwa wetu sasa, na hatuwezi kuahirisha matibabu mpaka ukweli wote ni kujulikana.
Kwa hiyo utaratibu wa majina hii inatokana na: -
1. haja ya kutibu sasa
2. Updated ufahamu sayansi ya ubongo
3. hukumu ya wajumbe wa kikosi kazi
4. dhana kwamba watoto kuendeleza na kwa hiyo masuala ya maendeleo (kwa mfano ini na figo, ubongo maendeleo jukwaa) lazima kuzingatiwa katika matumizi na kipimo.
Katika suala hili, sisi kuja na utaratibu wa majina kwamba ni inaendeshwa na: taaluma ya dawa na utaratibu wa utekelezaji. NBN huonyesha ujuzi wa sasa na ufahamu kuhusu neurotransmitters / molekuli / mifumo ya kuwa iliyopita + mode / utaratibu wa utekelezaji

4 vipimo clinically husika pia ni pamoja na:
1.Approved dalili - Kulingana na mapendekezo ya miili mikubwa ya udhibiti (kwa mfano FDA, EMA, nk) kwa kundi hili umri.
2. Utendakazi na upande athari - Lengo la kuonyesha hali ambapo kiwanja hana kibali rasmi kwa ajili ya dalili, lakini kuna ushahidi wa kuunga mkono matumizi yake katika dalili za ziada (s), kwa mfano pamoja na mkono miongozo mtaalam.
Katika athari sehemu, kubwa tu, kubadilisha maisha au umeenea madhara zimeorodheshwa.
3. "maelezo kivitendo" - muhtasari maarifa ya kiafya ambayo imekuwa "kuchujwa" ingawa kikosi kazi "ungo".
4. Neurobiology - Inayotokana data zilizopo.
Kwa wale ambao wangependa kujua zaidi kuhusu taaluma ya dawa kuna uhusiano wa moja kwa moja na tovuti muhimu za IUPHAR - mshirika wetu katika jitihada hii.

Kama hii ni mchakato inayoendelea, tunatambua kwamba kuna ni kwenda kuwa omissions. Kulingana na maoni yako, majibu wenzake wengine ( "hekima ya kliniki"), ripoti mpya na matokeo mapya, updates sahihi utafanywa.

NBN C & A embeds sasa sayansi ya ubongo maendeleo ili kutoa kina na thabiti mfumo kumtaja kwa ajili ya watoto na ujana. Jopokazi inatarajia kwamba itasaidia kliniki ya kufanya maamuzi katika "hatua psychopharmacological" na kwamba anafafanua Asili ya maagizo.